5-(苯磺酰基)-N-(哌啶-4-基)-2-(三氟甲基)苯磺酰胺
5-(苯磺酰基)-N-(哌啶-4-基)-2-(三氟甲基)苯磺酰胺
5-(苯磺酰基)-N-(哌啶-4-基)-2-(三氟甲基)苯磺酰胺 性质
沸点 | 601.1±65.0 °C(Predicted) |
---|---|
密度 | 1.50±0.1 g/cm3(Predicted) |
溶解度 | DMF:3mg/mL; DMSO:3mg/mL; DMSO:PBS (pH 7.2) (1:10):0.1 mg/mL |
酸度系数(pKa) | 8.76±0.20(Predicted) |
形态 | 粉末 |
颜色 | 白色至米白色 |
5-(苯磺酰基)-N-(哌啶-4-基)-2-(三氟甲基)苯磺酰胺 用途与合成方法
Target | Value |
sFRP1
() |
The EC 50 of WAY-316606 for Wnt-Luciferase Activity from U2-OS Cells is 0.65 μM. WAY-316606 binds to secreted frizzled-related protein (sFRP)-1 inhibitor with a K D of 0.08 μM and inhibits sFRP-1 with an EC 50 of 0.65 μM. WAY-316606 also binds to sFRP-2, albeit over 10 times weaker with a K D of 1 μM. Using a fluorescence polarization binding assay that employs a fluorescent probe compound and purified human sFRP-1 protein in a competitive-binding format, the IC 50 for WAY-316606 is 0.5 μM.
WAY-316606 increases bone formation when tested in a neonatal murine calvarial assay. WAY-316606 increases total bone area up to 60% in a dose-dependent manner with an EC 50 of about 1 nM. WAY-316606 has good aqueous solubility, moderate to low inhibition of cytochrome p450 isozymes (3A4, 2D6, 2C9) and good stability in rat and human liver microsomes (t 1/2 >60 min in each species). In female Sprague-Dawley rats, WAY-316606 exhibits high plasma clearance (77 mL/min/kg, greater than hepatic blood flow) following a single intravenous bolus dose (2 mg/kg), which results in a rapid decline of drug exposure in the plasma despite the route of administration.
5-(苯磺酰基)-N-(哌啶-4-基)-2-(三氟甲基)苯磺酰胺 价格(试剂级)
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024-11-08 | HY-10858 | 5-(苯磺酰基)-N-(哌啶-4-基)-2-(三氟甲基)苯磺酰胺 | 915759-45-4 | 5mg | 900 |
2024-11-08 | HY-10858 | 5-(苯磺酰基)-N-(哌啶-4-基)-2-(三氟甲基)苯磺酰胺 | 915759-45-4 | 10mM * 1mLin DMSO | 1000 |